Paulo Fontoura, MD, PhD

Dr. Fontoura examines the effect that ocrelizumab has on the composite end point of no evidence of disease progression in MS.


Limelight Video

Next Article:

Evaluation of Cortical Lesions Could Improve Diagnosis of MS

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge

Related Articles